# Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

Source: https://onco.cc/trials/nct03036098/  
OnCo record `nct03036098` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nivolumab, Ipilimumab, Gemcitabine, Cisplatin and Carboplatin in bladder & urothelial cancer, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT03036098 by Bristol-Myers Squibb, with 1314 participants enrolled, started 2017-03-24 and due to reach its primary completion in 2024-08-30. Interventions recorded: Nivolumab, Ipilimumab, Gemcitabine, Cisplatin and Carboplatin. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03036098
- Phase: 3
- Setting: A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer
- Sponsor: Bristol-Myers Squibb
- Enrolled: 1314

## Sources

- ClinicalTrials.gov NCT03036098: https://clinicaltrials.gov/study/NCT03036098

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Deciphera Pharmaceuticals (Ono)](https://onco.cc/companies/deciphera/)

---
JSON: https://onco.cc/api/v1/entities/nct03036098.json